Navigate the Infinity Pharma $INFI Research Pages
Introduction - General corporate updates, financials, and resources
Saridegib (IPI-926) - Hedgehog inhibitor in multiple phase 2 cancer trials
Retaspimycin HCl (IPI-504) - HSP90 inhibitor in phase 2 for lung cancer
IPI-145 - PI3K inhibitor in phase 1 for oncology and inflammatory diseases
Pipeline - including IPI-940 pain drug candidate licensed to Purdue Pharma
Saridegib (IPI-926) - Hedgehog inhibitor in multiple phase 2 cancer trials
Retaspimycin HCl (IPI-504) - HSP90 inhibitor in phase 2 for lung cancer
IPI-145 - PI3K inhibitor in phase 1 for oncology and inflammatory diseases
Pipeline - including IPI-940 pain drug candidate licensed to Purdue Pharma
IPI-940 FAAH inhibitor
- oral Fatty Acid Amide Hydrolase (FAAH) inhibitor
- Goal to boost body's anelgesic and anti-inflammatory response- develop for pain and inflammatory diseases
- 4/2011 webcast: FAAH breaks down anandamide- molecule produced to relieve pain. IPI- 940- blocks this enzyme, resulting in more natural analgesia. same MOA as medical marijuana
- October 2010: reported p1 results in 48 healthy volunteers demonstrated FAAH inhibition and increased anandamide levels. No DLT, add'l p1 development ongoing
- October 2010: Mundipharma/Purdue exercised option to assume worldwide development for the pgm and pay for all future costs. Program is transitioning to Purdue who will initiate phase 2 for pain in 2011
- 4/2011: this program handled differently vs rest of pipeline, transfer to Purdue earlier in development
- 6/2011 CC: on track with transition activities. 8/2011 2q11 CC: no update.
2012 Update: INFI has reacquired rights to the program but there has been no advancement and INFI will not further develop this drug without a partner - future is murky.
Discovery Programs (as of January 2011 Slides)
- Research collaboration with Intellikine to identify additional differentiated PI3K and/or PI3K inhibitors for development
- Bcl-2 specific and dual Bcl-2/Bcl-xL inhibitors (licensed to Novartis)
- Additional efforts directed toward emerging targets: Cancer metabolism, apoptosis, protein homeostasis, inflammation
- 6/2011 webcast: Expect to name a new development candidate in 2011
IPI-493 HSP90 Inhibitor - Discontinued
- orally bioavilable- 8/1/2007 PR announced the selection of IPI-493 as "a second ansamycin-class HSP90 inhibitor"...IPI-493 is the major active metabolite of 17-AAG and IPI-504 (see structures above)
- One US patent on COM and formulations expires 2027.
- EORTC 2008 poster: shows improved exposure with oral formulation. Click here for poster reprint
- Two ongoing phase 1 trials- advanced solid tumors and hemotological malignancies- to determine dose and schedule for future studies. Seeking evidence that client proteins are degraded in treated pts- a key milestone for continued investment in this program. Data from this trial will be analyzed by mid-2011 and used to determine the path forward for the HSP90 program
- 5/2011 PR and 6/2011 CC: Preliminary analysis of the two phase 1 trials complete. Decided to kill this program and advance IPI-504 due to better PK "drug exposure"..no comment of relative safety profile.
- 2011 AACR poster: treating mouse model with EGFR TKI followed by IPI-493 is effective. Click here for poster reprint
- 2011 AACR slide deck: all preclinical data. Click here for PDF file